FDA approved first immunotherapy for initial treatment of gastric cancer
On Apr. 16, 2021, the FDA approved Bristol-Myers Squibb’ s Opdivo (nivolumab), in combination with certain types of…
-
-
researchers discovered a gene that causes the most common form of muscular dystrophy in adults
On Apr. 15. 2021, a team of researchers led by the University of Minnesota Medical School announced they…
-
Global shortage of innovative antibiotics fueled emergence and spread of drug-resistance
On Apr. 15, 2021, the World Health Organization (WHO) reported that the world was still failing to develop…
-
Merck announced phase 2/3 MOVe-IN study in hospitalized patients stopped
On Apr. 15, 2021, Merck and Ridgeback Biotherapeutics, and Ridgeback Biotherapeutics announced that based on a planned interim…
-
Experimental antiviral for COVID-19 was effective in hamster study
On Apr. 15, 2021, the National Institutes of Health announced that the experimental antiviral drug MK-4482 significantly decreased…
-
IH closed enrollment in trial comparing COVID-19 treatment regimens
On Apr. 15, 2021, The National Institute of Allergy and Infectious Diseases (NIAID) announced that the fourth iteration…
-
CytoDyn executed agreement with Chiral Pharma to provide up to 200,000 vials of leronlimab to Philippines
On Apr. 15, 2021, CytoDyn announced it had executed an exclusive supply and distribution agreement with Chiral Pharma…
-
INOVIO’s COVID-19 vaccine candidate provided broad cross-reactive immune responses In humans against variants
On Apr. 15, 2021, Inovio Pharmaceuticals announced the results of a study focusing on the human immune responses…
-
Merck discontinued development of MK-7110 for COVID-19
On Apr. 15, 2021, Merck announced the discontinuation of development of MK-7110 (formerly known as CD24Fc) for the…
-
NIH funded new influenza research network
On Apr. 15, 2021, the National Institute of Allergy and Infectious Diseases (NIAID) announced it had had established…
-
Risk of rare blood clotting higher for COVID-19 than for vaccines
On Apr. 15, 2021, researchers at the University of Oxford reported that the risk of the rare blood…
-
Alternating vaccines trial expanded to include two additional vaccines
On Apr. 14, 2021, researchers running the Com-Cov study, launched in February to investigate alternating doses of the…
-
Moderna announced clinical progress from mRNA Vaccine
On Apr. 14, 2021, Moderna announced that results from a preclinical study of the Company’s COVID-19 variant-specific vaccine…
-
Mayo Clinic launched new technology platform ventures to revolutionize diagnostic medicine
On Apr. 14, 2021, the Mayo Clinic announced a new technology platform initiative to deliver the next generation…
-
Most differences in DNA binding compounds found at birth in children conceived by IVF not seen in early childhood
On Apr. 14, 2021, National Institutes of Health researchers reported that a study which compared to newborns conceived…
-
Novavax announced participation in University of Oxford Com-COV2 study comparing mixed COVID-19 vaccine combinations
On Apr. 14, 2021, Novavax announced its participation in an expanded investigator-initiated Phase 2 clinical trial called Comparing…
-
AstraZeneca announced update on the safety of COVID-19 vaccine
On Apr. 14, 2021, following concern raised around thrombotic events, AstraZeneca offered its reassurance on the safety of…
-
Positive topline data showed Fostamatinib met primary endpoint of safety in phase 2 clinical trial in hospitalized COVID-19 patients
On Apr. 13, 2021, Rigel Pharma announced the completion of patient enrollment in a multi-center Phase 2 clinical…
-
NIAID trial of Anti-CD14 antibody to treat COVID-19 respiratory disease began
On Apr. 13, 2021, a clinical trial testing the safety and efficacy of an investigational monoclonal antibody for…
-
Cardinal Health awarded Strategic National Stockpile contract for PPE storage and distribution
On Apr. 13, 2021, Cardinal Health was awarded a $57.8 million contract, including options that if exercised by…
-
Allen Discovery Center announced your life history is written in your cells’ mutations
On Apr. 13, 2020, the Allen Discovery Center for Human Brain Evolution announced a study that traced developmental…
-
FDA recommended pause in use of J&J vaccine after adverse events reported
On Apr. 13, 2021, the FDA and CDC announced that they were are reviewing data involving six reported…
-
Study linked structural brain changes to behavioral problems in children who snore
On Apr. 13, 2021, a large study of children has uncovered evidence that behavioral problems in children who…
-
Joint CDC and FDA statement on Johnson & Johnson COVID-19 vaccine
As of Apr. 12, 2021, more than 6.8 million doses of the Johnson & Johnson (Janssen) vaccine were…
-
Moderna updated clinical and supply on COVID-19 vaccine program
On Apr. 13, 2021, Moderna announced that new results from a preclinical study of the Company’s COVID-19 variant-specific…
-
FDA authorized new high-throughput, automated system for leading COVID-19 test
On Apr. 12, 2021, Thermo Fisher Scientific announced that the U.S. Food and Drug Administration (FDA) had granted…
-
Asthma drug budesonide shortened recovery time in non-hospitalised patients with COVID-19
On Apr. 12, 2021, Oxford University reported that early treatment with inhaled budesonide shortened recovery time by a…
-
Phase III trial showed subcutaneous administration of investigational antibody cocktail reduced risk of symptomatic COVID-19 infections by 81%
On Apr. 12, 2021, Roche confirmed positive results from the phase III REGN-COV 2069 trial assessing the ability…
-
Health Canada Issued Resverlogix authorization to begin immediate clinical studies of apabetalone for COVID-19
On Apr. 12, 2021, Resverlogix announced that it had successfully received its desired ‘No Objection Letter’ from Health…
-
Biotechnology | COVID-19 | NIH | Therapeutics | Vaccine
NIH COVID-19 treatment guidelines strongly recommended Use of REGEN-COV in high risk outpatients
On Apr. 9, 2021, Regeneron announced that newly updated National Institutes of Health (NIH) COVID-19 treatment guidelines strongly…
